Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy

Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy

Abstract Background To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y12 receptor inhibitor. Clopidogrel is a prodrug requiring activation by the cytochrome P450 enzy...

Full description

Bibliographic Details
Main Authors: Abdullah M. Al-Rubaish, Fahad A. Al-Muhanna, Abdullah M. Alshehri, Mohammed A. Al-Mansori, Rudaynah A. Alali, Rania M. Khalil, Khalid A. Al Faraidy, Cyril Cyrus, Mohammed M. Sulieman, Chittibabu Vatte, Daniel M. F. Claassens, Jurriën M. ten Berg, Folkert W. Asselbergs, Amein K. Al-Ali
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Cardiovascular Disorders
Subjects:
Clopidogrel
Ticagrelor
Prasugrel
Platelet aggregation inhibitor
King Fahd hospital
Purinergic P2 receptor antagonists
Online Access:http://link.springer.com/article/10.1186/s12872-020-01558-2

Internet

http://link.springer.com/article/10.1186/s12872-020-01558-2

Similar Items